995 related articles for article (PubMed ID: 21848902)
41. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
[TBL] [Abstract][Full Text] [Related]
42. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.
Lefaucheur C; Suberbielle-Boissel C; Hill GS; Nochy D; Andrade J; Antoine C; Gautreau C; Charron D; Glotz D
Contrib Nephrol; 2009; 162():1-12. PubMed ID: 19001809
[TBL] [Abstract][Full Text] [Related]
43. Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid-phase assays.
Verghese PS; Smith JM; McDonald RA; Schwartz SM; Nelson KA; Warner PR
Pediatr Transplant; 2010 Sep; 14(6):730-4. PubMed ID: 20598090
[TBL] [Abstract][Full Text] [Related]
44. B cell positive cross-match not due to anti-HLA Class I antibodies and first kidney graft outcome.
Praticò-Barbato L; Conca R; Magistroni P; Leonardi G; Oda A; Rosati F; Leone E; Tacconella M; Roggero S; Segoloni GP; Amoroso A
Transpl Immunol; 2008 Jul; 19(3-4):238-43. PubMed ID: 18675725
[TBL] [Abstract][Full Text] [Related]
45. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
46. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
47. Mothers without HLA antibodies before transplantation have a low risk of alloimmunization post-transplantation.
Gatault P; Jollet I; Rabot N; Boulanger MD; Taupin JL; Barbet C; Baron C; Thierry A; Halimi JM; Lebranchu Y; Touchard G; Büchler M
Tissue Antigens; 2011 Oct; 78(4):241-8. PubMed ID: 21929572
[TBL] [Abstract][Full Text] [Related]
48. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.
Dignan R; O'Brien M; Hogan P; Thornton A; Fowler K; Byrne D; Stephens F; Harrocks S
J Heart Valve Dis; 2003 May; 12(3):382-90; discussion 390-1. PubMed ID: 12803340
[TBL] [Abstract][Full Text] [Related]
49. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.
Arnold ML; Ntokou IS; Doxiadis II; Spriewald BM; Boletis JN; Iniotaki AG
Transpl Int; 2014 Mar; 27(3):253-61. PubMed ID: 24118579
[TBL] [Abstract][Full Text] [Related]
50. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
51. Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome.
Varnavidou-Nicolaidou A; Iniotaki-Theodoraki AG; Doxiadis II; Georgiou D; Patargias T; Stavropoulos-Giokas C; Kyriakides G
Hum Immunol; 2005 Sep; 66(9):985-8. PubMed ID: 16360838
[TBL] [Abstract][Full Text] [Related]
52. 14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysis.
Ozawa M; Terasaki PI; Castro R; Alberu J; Morales-Buenrostro L; Alvarez I; Toledo R; Alvez H; Monteiro M; Teixeira J; Campbell P; Ciszek M; Charron D; Gautreau C; Christiansen F; Langan L; Conca R; Grosse-Wilde H; Heinemann F; Kamoun M; Kobayashi T; Kupatawintu P; LeFor W; Mehra N; Panigrahi A; Norman D; Piazza A; Poli F; Roy R; Schonemann C; Lachmann N; Sireci G; Tanabe K; Ishida H; Van den Berg-Loonen E; Zeevi A
Clin Transpl; 2007; ():255-60. PubMed ID: 18642456
[TBL] [Abstract][Full Text] [Related]
53. Allosensitization to HLA and MICA is an important measure of renal graft outcome.
Panigrahi A; Siddiqui JA; Rai A; Margoob A; Khaira A; Bhowmik D; Tiwari SC; Guleria S; Mehra NK
Clin Transpl; 2007; ():211-7. PubMed ID: 18637472
[TBL] [Abstract][Full Text] [Related]
54. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
55. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy.
Martin L; Guignier F; Mousson C; Rageot D; Justrabo E; Rifle G
Transplantation; 2003 Jul; 76(2):395-400. PubMed ID: 12883199
[TBL] [Abstract][Full Text] [Related]
56. Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations.
Dieplinger G; Ditt V; Arns W; Huppertz A; Kisner T; Hellmich M; Bauerfeind U; Stippel DL
Transpl Int; 2014 Jan; 27(1):60-8. PubMed ID: 24131087
[TBL] [Abstract][Full Text] [Related]
57. A novel ELISA-based crossmatch procedure to detect donor-specific anti-HLA antibodies responsible for corneal allograft rejections.
Sel S; Schlaf G; Schurat O; Altermann WW
J Immunol Methods; 2012 Jul; 381(1-2):23-31. PubMed ID: 22561526
[TBL] [Abstract][Full Text] [Related]
58. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation.
Le Bas-Bernardet S; Hourmant M; Valentin N; Paitier C; Giral-Classe M; Curry S; Follea G; Soulillou JP; Bignon JD
Transplantation; 2003 Feb; 75(4):477-82. PubMed ID: 12605113
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value and cost-effectiveness of different screening strategies for HLA antibodies prior to kidney transplantation.
Ziemann M; Schönemann C; Bern C; Lachmann N; Nitschke M; Fricke L; Görg S
Clin Transplant; 2012; 26(4):644-56. PubMed ID: 22432638
[TBL] [Abstract][Full Text] [Related]
60. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
